Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

LMO2 (LIM domain only 2 (rhombotin-like 1))

Identity

Other namesRBTN2 (rhombotin-2)
RHOM2
RBTNL1 (rhombotin-like-1)
TTG2 (T-cell translocation gene 2)
LMO2 (LIM domain only 2)
HGNC LMO2
Location 11p13
Local_order telomere LMO1 - NUP98 (11p15) - CD59 - FSHB - LMO2 - PAX6 - PDHX (11p13) centromere.

DNA/RNA

Description LMO2 belongs to a multigene family, extremely well conserved during evolution, encoding proteins containing two cystein-rich regions referred to as LIM domains: LMO1 (11p15), LMO2 (11p13), LMO3 (12p); 6 exons.
Transcription 3 transcripts: LMO2-a and LMO2-b encode the same 158-amino-acid protein; LMO2-c encodes a 151-amino-acid protein.

Protein

Description Small cystein rich protein with two tandemly arranged Zinc binding LIM domain motifs: named Lom2; 158 amino acids; 18 kDa; 48 % amino-acid identity with LMO1 protein.
LMO2 contains two transcription activating domains (one in N-term, in a prolin-rich 19 amino acid region, one in C-term) and two LIM domains as transcription repressing domains, selectively inhibiting the N-term activation domain (no effect on the C-term domain).
Expression Early expressed during development, in all tissues (roughly consistent level in central nervous system, low level in thymus).
Strongly expressed in the precursors of mixed erythrocyte/macrophage/mast, erythrocyte, megakaryocyte, neutrophil and macrophage colonies, undetectable in the mature progeny.
Expressed in early B-cells, in leukemias of both the myeloid and lymphoid lineages.
Nuclear marker in normal germinal center B-cells. Also expressed in endothelial cells. High expression in the brain; expressed in the hippocampus during development.
Localisation Nuclear.
Function
  • Hematopoiesis: LMO2 directly interacts with the basic-loop-helix protein TAL1/SCL and the GATA DNA protein GATA1. They form a transcriptional complex: LMO2 has no direct evidence in DNA binding capacity but could act as a bridging molecule bringing together different DNA binding factors (TAL1, LDB1, E12/E47, GATA1) that are essential for hematopoiesis (e.g. in the erythroid complex). This interaction is critical for the regulation of red blood cell development in early stages of hematopoiesis. TAL1 interacts specifically with the LIM domains of LMO2, which in turn binds LDB1. Because LMO2 can also bind to GATA2, a complex LMO2-GATA2 might occur at earlier stages of hematopoiesis when Gata1 is not expressed. Lmo2 has a central role in adult hematopoietic pathway regulation, on bone marrow pluripotential precursor stem cell mainly. LMO2 and TAL1 are able to partially suppress myeloid differentiation. LMO2 also interacts with retinoblastoma-binding protein 2 and elf-2 (ets transcription factor).
  • LMO2-c expression is regulated by GATA1 and PU.1; LMO2-c acts as an antagonist of LMO2-a/b, therefore blocking the transactivation of LMO2-a/b.
  • In the brain, hBEX2, LMO2, NSCL2 and LDB1 could form a similar complex.
  • Implicated in

    Entity t(11;14)(p13;q11)/T-cell leukaemia --> LMO2 - TCRD-A
    Disease Childhood T-cell ALL ; found in 5-10% of T-cell ALL.
    Cytogenetics A variant translocation t(7;11)(q35;p13) has been described.
    Abnormal Protein It was previously believed that LMO2 is activated after chromosomal translocation by association either the T-cell receptor a / T-cell receptor d (14q11) or T-cell receptor b gene (7q35). Chromosome breakpoints occur 25 kb upstream LMO2 gene, in a presumed transcriptional start site, inducing truncation of the promoter/control region and leading to inappropriate Lmo2 level especially in T-cells (abnormal T-cell differentiation). However, it becomes now very likely that removal of a negative regulatory element from the LMO2 locus, rather than juxtaposition to the TCRD enhancer, is the main determinant for LMO2 activation in the majority of t(11;14)(p13;q11) translocations.
      
    Entity del(11)(p12p13) T-cell leukaemia
    Disease Childhood T-cell ALL; found in about 5% of T-cell ALL.
    Cytogenetics Cryptic deletion that varies in size.
    Abnormal Protein LMO2 is activated through a cryptic intrachromosomal deletion, del(11)(p12p13), in which a negative regulatory element (NRE), situated upstream of the LMO2 gene, is deleted. Removal of this NRE causes activation of the proximal promoter of the LMO2 gene leading to its ectopic expression.
      
    Entity Germinal center B-cell lymphomas
    Disease Diffuse large-B-cell lymphomas, follicular lymphomas, Burkitt lymphomas, less often in other haematological malignancies.
    Prognosis LMO2 expression, together with BCL6, FN1, CCND2, SCYA3, and BCL2 expressions, is a predictor of outcome in diffuse large-B-cell lymphoma.
      
    Entity Prostate cancer
    Note Expression of LMO2 is higher in prostate tumours samples than in the normal epithelium. Moreover, overexpression of LMO2 is significantly associated with advanced tumour stage, as well as with the development of distant metastasis.
    Oncogenesis LMO2 may play an important role in prostate cancer progression, possibly via repression of E-cadherin expression.
      

    External links

    Nomenclature
    HGNCLMO2   6642
    Entrez_GeneLMO2  4005  LIM domain only 2 (rhombotin-like 1)
    Cards
    AtlasRBTN2ID34
    GeneCardsLMO2
    EnsemblLMO2 [Search_View]   ENSG00000135363 [Gene_View]
    GenatlasLMO2
    GeneLynxLMO2
    eGenomeLMO2
    euGene4005
    Genomic and cartography
    GoldenPathLMO2  -  11p13   chr11:33836699-33870412 -  11p13   [Description]    (hg18-Mar_2006)
    EnsemblLMO2 - 11p13 [CytoView]
    NCBIMapview
    OMIMDisease map [OMIM]
    HomoloGeneLMO2
    Gene and transcription
    GenbankAF257211 [ ENTREZ ]
    GenbankBC034041 [ ENTREZ ]
    GenbankBC035607 [ ENTREZ ]
    GenbankBC042426 [ ENTREZ ]
    GenbankBC073973 [ ENTREZ ]
    RefSeqNM_005574 [ SRS ]    NM_005574 [ ENTREZ ]
    RefSeqAC_000054 [ SRS ]    AC_000054 [ ENTREZ ]
    RefSeqAC_000143 [ SRS ]    AC_000143 [ ENTREZ ]
    RefSeqNC_000011 [ SRS ]    NC_000011 [ ENTREZ ]
    RefSeqNT_009237 [ SRS ]    NT_009237 [ ENTREZ ]
    RefSeqNW_001838022 [ SRS ]    NW_001838022 [ ENTREZ ]
    RefSeqNW_925006 [ SRS ]    NW_925006 [ ENTREZ ]
    AceViewLMO2 AceView - NCBI
    UnigeneHs.34560 [ SRS ]    Hs.34560 [ NCBI ]     HS34560 [ spliceNest ]
    Fast-db4806 (alternative variants)
    Protein : pattern, domain, 3D structure
    SwissProtP25791 [ SRS]    P25791 [ EXPASY ]     P25791 [ INTERPRO ]     P25791 [ UNIPROT ]
    PrositePS00478 LIM_DOMAIN_1 [ SRS ]    PS00478 LIM_DOMAIN_1 [ Expasy ]
    PrositePS50023 LIM_DOMAIN_2 [ SRS ]    PS50023 LIM_DOMAIN_2 [ Expasy ]
    InterproIPR001781 Znf_LIM [ SRS ]    IPR001781 Znf_LIM [ EBI ]
    CluSTrP25791
    PfamPF00412 LIM [ SRS ]    PF00412 LIM [ Sanger ]    pfam00412 [ NCBI-CDD ]
    SmartSM00132 LIM [EMBL]
    ProdomPD000094 LIM[INRA-Toulouse]
    ProdomP25791 RBTN2_HUMAN [ Domain structure ]   P25791 RBTN2_HUMAN  [ sequences sharing at least 1 domain ]
    BlocksP25791
    HPRD01586
    Protein Interaction databases
    DIPP25791
    IntActP25791
    Polymorphism : SNP, mutations, diseases
    OMIM180385    [ map ]   
    GENECLINICS180385
    SNPLMO2 [dbSNP-NCBI]  
    SNPNM_005574 [SNP-NCI]  
    SNPLMO2 [GeneSNPs - Utah]  LMO2] [HGBASE - SRS]
    HAPMAPLMO2 [HAPMAP]  
    COSMICLMO2 [Somatic mutation (COSMIC-CGP-Sanger)]  
    TICdbLMO2 [Translocation breakpoints In Cancer]  
    HGMDLMO2
    General knowledge
    Family BrowserLMO2 [UCSC Family Browser]
    SOURCENM_005574
    SMDHs.34560
    SAGEHs.34560
    GOprotein binding [Amigo]  protein binding
    GOnucleus [Amigo]  nucleus
    GOmulticellular organismal development [Amigo]  multicellular organismal development
    GOzinc ion binding [Amigo]  zinc ion binding
    GOmetal ion binding [Amigo]  metal ion binding
    PubGeneLMO2
    TreeFamLMO2
    CTD4005 [Comparative ToxicoGenomics Database]
    Other databases
    Probes
    ProbeLMO2 Related clones (RZPD - Berlin)
    PubMed
    PubMed40 Pubmed reference(s) in LocusLink

    Bibliography

    The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13.
    Boehm T, Foroni L, Kaneko Y, Perutz MF, Rabbitts TH
    Proceedings of the National Academy of Sciences of the United States of America. 1991 ; 88 (10) : 4367-4371.
    PMID 2034676
     
    TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11).
    Royer-Pokora B, Loos U, Ludwig WD
    Oncogene. 1991 ; 6 (10) : 1887-1893.
    PMID 1923511
     
    Expression of rhombotin 2 in normal and leukaemic haemopoietic cells.
    Dong WF, Billia F, Atkins HL, Iscove NN, Minden MD
    British journal of haematology. 1996 ; 93 (2) : 280-286.
    PMID 8639417
     
    The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins.
    Wadman IA, Osada H, Grˆºtz GG, Agulnick AD, Westphal H, Forster A, Rabbitts TH
    The EMBO journal. 1997 ; 16 (11) : 3145-3157.
    PMID 9214632
     
    The T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis.
    Yamada Y, Warren AJ, Dobson C, Forster A, Pannell R, Rabbitts TH
    Proceedings of the National Academy of Sciences of the United States of America. 1998 ; 95 (7) : 3890-3895.
    PMID 9520463
     
    Globin gene activation during haemopoiesis is driven by protein complexes nucleated by GATA-1 and GATA-2.
    Anguita E, Hughes J, Heyworth C, Blobel GA, Wood WG, Higgs DR
    The EMBO journal. 2004 ; 23 (14) : 2841-2852.
    PMID 15215894
     
    Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
    Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R
    The New England journal of medicine. 2004 ; 350 (18) : 1828-1837.
    PMID 15115829
     
    Negative regulatory elements are present in the human LMO2 oncogene and may contribute to its expression in leukemia.
    Hammond SM, Crable SC, Anderson KP
    Leukemia research. 2005 ; 29 (1) : 89-97.
    PMID 15541480
     
    Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex.
    Han C, Liu H, Liu J, Yin K, Xie Y, Shen X, Wang Y, Yuan J, Qiang B, Liu YJ, Peng X
    Nucleic acids research. 2005 ; 33 (20) : 6555-6565.
    PMID 16314316
     
    The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.
    Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER, Veerman AJ, Kamps WA, Meijerink JP, Pieters R
    Blood. 2006 ; 108 (10) : 3520-3529.
    PMID 16873670
     
    Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL.
    Dik WA, Nadel B, Przybylski GK, Asnafi V, Grabarczyk P, Navarro JM, Verhaaf B, Schmidt CA, Macintyre EA, van Dongen JJ, Langerak AW
    Blood. 2007 ; 110 (1) : 388-392.
    PMID 17360939
     
    The Lim-only protein LMO2 acts as a positive regulator of erythroid differentiation.
    Hansson A, Zetterblad J, van Duren C, Axelson H, Jˆnsson JI
    Biochemical and biophysical research communications. 2007 ; 364 (3) : 675-681.
    PMID 17964543
     
    Protein stability and transcription factor complex assembly determined by the SCL-LMO2 interaction.
    Lˆ©cuyer E, Lariviˆ®re S, Sincennes MC, Haman A, Lahlil R, Todorova M, Tremblay M, Wilkes BC, Hoang T
    The Journal of biological chemistry. 2007 ; 282 (46) : 33649-33658.
    PMID 17878155
     
    The significance of LMO2 expression in the progression of prostate cancer.
    Ma S, Guan XY, Beh PS, Wong KY, Chan YP, Yuen HF, Vielkind J, Chan KW
    The Journal of pathology. 2007 ; 211 (3) : 278-285.
    PMID 17167821
     
    The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas.
    Natkunam Y, Zhao S, Mason DY, Chen J, Taidi B, Jones M, Hammer AS, Hamilton Dutoit S, Lossos IS, Levy R
    Blood. 2007 ; 109 (4) : 1636-1642.
    PMID 17038524
     
    A novel transcript of the LMO2 gene, LMO2-c, is regulated by GATA-1 and PU.1 and encodes an antagonist of LMO2.
    Wang Q, Zhang M, Wang X, Yuan W, Chen D, Royer-Pokora B, Zhu T
    Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2007 ; 21 (5) : 1015-1025.
    PMID 17361224
     
    A highly conserved regulatory element controls hematopoietic expression of GATA-2 in zebrafish.
    Yang Z, Jiang H, Zhao F, Shankar DB, Sakamoto KM, Zhang MQ, Lin S
    BMC developmental biology. 2007 ; 7 : page 97.
    PMID 17708765
     
    REVIEW articlesautomatic search in PubMed
    Last year publicationsautomatic search in PubMed

    Search in all EBI   NCBI

    Contributor(s)

    Written06-1998Chrysthèle Bilhou-Nabera
    Cytogenetique, Laboratoire d'Hematologie-Pr Raphael, Pav Broca - 4eme étage, 78 rue du General Leclerc, 94275 Le Kremlin-Bicetre, France
    Updated11-2007Pieter Van Vlierberghe, Jean Loup Huret
    ErasmusMC/Sophia Children's Hospital, Pediatric Oncology/Hematology, Rotterdam, The Netherlands (PVV); Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

    Citation

    This paper should be referenced as such :
    Bilhou-Nabera C . LMO2 (LIM domain only 2 (rhombotin-like 1)). Atlas Genet Cytogenet Oncol Haematol. June 1998 .
    URL : http://AtlasGeneticsOncology.org/Genes/RBTN2ID34.html
    Van Vlierberghe P, Huret JL . LMO2 (LIM domain only 2 (rhombotin-like 1)). Atlas Genet Cytogenet Oncol Haematol. November 2007 .
    URL : http://AtlasGeneticsOncology.org/Genes/RBTN2ID34.html

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Mon Aug 11 21:17:03 2008


    Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us

    j.l.huret@chu-poitiers.fr.